Johnson & Johnson (JNJ) has been a stellar performer for us, rising close to 13% including dividend payments over a difficult period of time for the market. However, we are close to our target price, and I think the safety name in the trade is just about played out. Given the uncertainty of earnings after a top-selling drug in Stelara goes off patent next year, I think the shares will not outperform at the current price.

Sell JNJ. If you are an Inner circle subscriber following the model portfolio, Sell JNJ.